This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.
After PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding.
This study is not testing any new intervention, rather comparing approved drugs and approved durations of use.
≥18 years old
Admitted because of an acute MI (either STEMI or NSTEMI).
Invasive management during index admission with successful PCI.
Able to consent.
Indication for oral anticoagulation therapy.
Intolerance, contraindication or known allergy to either aspirin, prasugrel or ticagrelor.
Prior history of ischaemic or haemorrhagic stroke or transient ischaemic attack.
Patients with active bleeding or known bleeding disorders.
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Collaborator